skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Download Your Whitepaper Today

In response to recent data fraud findings, the China Food and Drug Administration (CFDA) has ruled that its approved generic drugs be retested. For pharmaceutical companies, investigators, and CROs there is more pressure than ever to improve drug quality and reporting— or be blacklisted.

Can you trust BE drug trial results from China, and is it advisable for pharma companies to plan their next study there?

Get answers to these and other burning questions when you download this whitepaper from Citeline. Leveraging real-time data intelligence from Trialtrove, the industry’s most comprehensive, accurate and up-to-date source of pharmaceutical clinical trials data, this paper dives deep into the history, current landscape and future of bioequivalence studies in China including:

  • The major players sponsoring BE trials now, and the drugs they are testing
  • Disease patient segmentation and protocol design
  • Targeted investigator details
  • Provinces with the most and least activity





電話:+81 (0)3 6273 4260